Evidence map›Paper›PMID 33225233›Full record

ArticleCardiovascular endocrinology & metabolism2020

The FreeStyle Libre flash glucose monitoring system: how it has improved glycaemic control for people with type 1 diabetes in Eastern Cheshire, UK.

Ghasem Yadegarfar, Simon G Anderson, Zohaib Khawaja, Gabriela Cortes, Kathryn Leivesley, Ann Metters, Linda Horne, Tom Steele, Adrian H Heald

Open access · diamondAbstract read
In one paragraph

Article in Cardiovascular endocrinology & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.Cardiovascular endocrinology & metabolism · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Ghasem YadegarfarThe School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, UK.
Simon G AndersonUniversity of the West Indies, Cave Hill Campus Barbados, Barbados.
Zohaib KhawajaDepartment of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK.
Gabriela CortesHigh Speciality Regional Hospital of Ixtapaluca, Mexico City, Mexico.
Kathryn LeivesleyVernova Healthcare, Watersgreen Medical Centre, Macclesfield, UK.
Ann MettersVernova Healthcare, Watersgreen Medical Centre, Macclesfield, UK.
Linda HorneVernova Healthcare, Watersgreen Medical Centre, Macclesfield, UK.
Tom SteeleVernova Healthcare, Watersgreen Medical Centre, Macclesfield, UK.
Adrian H HealdThe School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, UK.
Salford Royal Hospital · GBManchester Academic Health Science Centre · GBUniversidad México Contemporáneo · MXUniversity of the West Indies · BB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMany people with type 1 diabetes continue to run high HbA1c levels with associated elevated risk of cardiovascular events and increased mortality. We describe here how use of the FreeStyle Libre flash monitor has improved the glycaemic control of many people with type 1 diabetes where the new technology has been intensively deployed.

methodsWe report the outcomes of 92 consecutive adults (18 years of age or more) with type 1 diabetes who have begun using the FreeStyle Libre flash glucose monitor in East Cheshire, UK. Initiation was with education and support from one of the diabetes specialist nurses. An HbA1c of 60 mmol/mol (7.6%) was taken as the threshold for suboptimal glycaemic control.

resultsThe mean cohort age was 43 years for men and 39 years for women (overall range 17-83 years). In 92 consecutive users, HbA1c decreased by an average of 10.7 mmol/mol (0.98%) after 3 months, and by 16.1 mmol/mol (1.47%) after 6 months. There was also a narrowing of the distribution of HbA1c, with many fewer people running high HbA1c ≥80 mmol/mol (9.5%). After the 6-month follow-up, two 2/92 users did not wish to continue with the monitoring.

conclusionFlash glucose monitoring has great potential for the management of type 1 diabetes in the adult population and improving metabolic control/quality of life for people across the world. The technology provides significantly more data than the intermittent results obtained by traditional subcutaneous blood glucose monitoring, which may not capture intervals of extreme variability or nocturnal events.

Indexed as

cardiovascularflash blood glucose monitoringglycaemic controlHbA1ctype 1 diabetes

Identifiers

PMID33225233
PMCPMC7673768
OpenAlexW3036232444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.